



# Webinar

### 15 March 2024 14:30-16:00 CET

## **GoToMeeting** (online)

# **Developing Target Product Profiles for Antibiotics**

### Moderated by



Frederik Deroose

**Speakers:** 



Erin Duffy

CARB-X

Decisions on **disease targets** and whether to aim for oral or intravenous administration of a **new compound** requires complex decisions, involving the desires, needs and expectations of patients, healthcare organisations and regulators across the globe.

Developing Target Product Profiles (TPP) is a challenge for antibiotics development. In this webinar, speakers from CARB-X, Evotec and GSK will discuss TPPs in relation to aims, timing, scope and flexibility. The discussion will discuss the need for TPPs across the development life-cycle: from drug discovery to clinical trials, taking into account both clinical pathways, the area of application and market considerations.

innovative medicines initiative

efpia



Francesca Bernardini Evotec



Gareth Maher-Edwards GSK

### >> REGISTER HERE <<

For additional information please contact Frederik Deroose: frederik@connectingpharma.be



The COMBINE project has received funding from the Innovative innovation programme and EFPIA companies' in kind contribution.





# Webinar

### 15 March 2024 14:30-16:00 CET

### *GoToMeeting* (online)

# **Developing Target Product Profiles for Antibiotics**

#### Agenda

14:30	Welcome and introduction	Frederik Deroose, Chair of AMR Accelerator Scientific Interest Groups, Connecting Pharma
14:35	How CARB-X is expecting a TPP to be included in funding applications: talk on purpose & features of the TPP	Erin Duffy, Chief of R&D, CARB-X
14:50	How is Evotec developing a TPP in different stages of R&D in AMR?	Francesca Bernardini, Vice President, In Vitro Biology, Evotec
15:05	How GSK is developing a TPP in development and clinical stages: talk on involvement of clinicians in TPP development	Gareth Maher-Edwards, Scientific Director, Global Health, GSK
15:20	Panel discussion	All

#### **REGISTRATION IS MANDATORY**

For additional information please contact Frederik Deroose: frederik@connectingpharma.be

innovative medicines initiative

Imi

efpia

https://www.imi.europa.eu/

The COMBINE project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No 853967. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA companies' in kind contribution.